Bayer AG’s deal to buy Merck & Co. Inc.’s consumer unit is coupled with a pact to jointly develop and commercialize soluble guanylate cyclase (sGC) modulators, including Bayer’s already approved Adempas (riociguat).
Under the consumer health transaction, announced May 6, Bayer will pay Merck $14.2 billion for the business, which many analysts...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?